Clinical Trial Update: Study of ADI-PEG 20 in Patients With Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of ADI-PEG 20 in advanced melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Metastatic Melanoma, Skin Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-26